Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib + Pembrolizumab + Gemcitabine in Advanced Cancer
NCT02546531Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Feb 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of defactinib in pancreatic cancer (PC) and solid tumor (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Recommended phase II dose at 25 months. Started Feb 2016; status: completed.
02
Drugs
defactinib
03
Conditions
pancreatic cancer (PC)solid tumor
Beyond the preview
Go deeper on NCT02546531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546531.